Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer
NCT06196671
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
30
Enrollment
OTHER
Sponsor class
Conditions
Pancreatic Cancer
Interventions
DRUG:
H101
DRUG:
Camrelizumab
Sponsor
Fudan University